NCT00038493View on ClinicalTrials.gov

Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 21, 2001

Primary Completion Date

August 1, 2005

Study Completion Date

August 1, 2005

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Temozolomide and SCH66336

Trial Locations (1)

77030

UTMD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00038493 - Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter